Artis BioSolutions, a San Diego, CA-based company which specializes in the development and production of genetic medicines, raised an undisclosed amount in funding.
The round was led by Oak HC/FT.
The company intends to use the funds to further build out the services and technology platform and accelerate future growth. Artis also announced the acquisition of Landmark Bio for an undisclosed amount. With this deal, Artis BioSolutions will advance therapy developers looking for end-to-end capabilities within the category of advanced therapies.
Led by CEO Ran Zheng, Landmark Bio accelerates the development and industrialization of novel therapeutics. It specializes in drug development, creating accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come.
Led by CEO Brian Neel and CSO Mike Houston, Artis BioSolutions develops and produces genetic medicines. Designed to support treatments, it offers technology, deep expertise, and a client-focused approach to streamline processes, improve efficiency, and scale across various therapeutic areas. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute.
FinSMEs
02/04/2025